Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease

Bangerter, Markus; Moog, Florian; Buchmann, Inga; Kotzerke, Jörg; Grießhammer, Martin; Häfner, Matthias; Elsner, Klaus; Frickhofen, Norbert; Reske, Sven N.; Bergmann, Lothar

doi:10.1023/a:1008486928190

Cited by 220 publications

(107 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our own data obtained in quite a large number of patients unequivocally documented the therapeutic relevance of 18 F-FDG-PET for patients with HL. The prospective study of Bangerter et al (1998) entailed a change in treatment in six of 44 patients (14%). Jerusalem et al (2001) investigated 33 patients with HL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

et al. 2004

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…F-fluorodeoxyglucose positron emission tomography as a sensitive method for the detection of bone marrow infiltration can provide additional information to that of bone marrow biopsy in the staging of malignant lymphomas (Bangerter et al, 1998;Carr et al, 1998;Moog et al, 1998b;Naumann and Beuthien-Baumann, in press). …”

mentioning

confidence: 99%

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

et al. 2004

View full text Add to dashboard Cite

“…18 FFluorodeoxyglucose (FDG) positron emission tomography (PET) has emerged as a useful functional imaging tool for staging, restaging, and response assessment of lymphomas [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Its main advantage over morphological imaging modalities in assessing response to therapy is its ability to distinguish between viable tumor and necrosis or fibrosis in residual masses often present after treatment.…”

Section: Introductionmentioning

confidence: 99%

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

Metser

Mohan

Beckley

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Based on the International Harmonization Project (IHP) criteria, positron emission tomography (PET) response assessment of residual nodal masses in patients with lymphoma after completion of therapy is performed visually using mediastinal blood pool as the reference. The primary objective of this study was to define the optimal reference for PET response assessment. Secondary aim was to assess if morphological criteria on computed tomography (CT) may improve performance of PET. Methods This institutional review board approved retrospective study included 137 patients, with Hodgkin's (n=43) or non-Hodgkin's lymphoma (n = 94) assessed for residual masses (n=180) after completion of therapy with pathology and clinical and imaging surveillance data (mean, 19 months) as the standard of reference. Two readers independently assessed response by IHP and Deauville criteria. The addition of morphological parameters on CT was assessed in relation to therapy response.Results Based on the standard of reference, 36 patients (26.3 %) had residual lymphoma. For IHP and Deauville criteria, sensitivity, specificity and accuracy were 97.2 %, 97.2 % (p= 1); 79.2 %, 92.1 % (p< 0.001); and 83.9 %, 93.4 % (p=0.001), respectively. Of the morphological parameters assessed, only change in size over course of therapy was significant (p<0.003) and improved specificity for IHP-based interpretation to 90.4 % (p=0.008). Conclusions Using liver as the visual reference to determine PET positivity for lymphoma patients being assessed for residual masses at the end of therapy improves specificity, yet maintains the high sensitivity of PET in identifying residual disease. The addition of change in size after therapy improves specificity of PET when using IHP-based but not Deauvillebased interpretation.

show abstract

“…Preliminary data suggest that FDG-PET is a useful tool to stage and monitor lymphoma. [13][14][15][16][17][18][19][20][21][22][23] However, there has been scarce data comparing FDG-PET and Ga-67 scintigraphy; thus, their comparative value is still conjectural. 13,24,25 Accordingly, we prospectively compared the accuracy of whole-body FDG-PET and Ga-67 scintigraphy to identify disease sites in HD and non-Hodgkin lymphoma (NHL; intermediate grade and high grade) at initial staging or recurrence before chemotherapy.…”

mentioning

confidence: 99%

Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

Kostakoğlu

Leonard

Kuji

et al. 2002

Cancer

179

View full text Add to dashboard Cite

Ga-67 SPECT failed to demonstrate disease at 45 sites (35.7%). In 10 of 44 patients, Ga-67 SPECT completely failed to detect any disease at 22 of 45 sites (17.5%) and partially identified disease sites at 23 of 45 sites (18.2%) in 11 patients regardless of the tumor site and histology. In these patients, the lesions measured between 0.6 and 14.0 cm by CT. Fluorodeoxyglucose positron emission tomography revealed higher stage disease in 13 patients compared with Ga-67 imaging. Tumor-tobackground ratios were statistically different between the two techniques with

show abstract

Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease

Abstract: Our data indicate that FDG-PET provides an imaging technique that appears to visualize involved lesions in most patients with HD and is useful in the management of these patients.

Cited by 220 publications

References 27 publications

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

Contact Info

Product

Resources

About